Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery

समान संसाधन

• ACTR-58. BASELINE REQUIREMENTS FOR NOVEL AGENTS BEING CONSIDERED FOR BRAIN CANCER EFFICACY TRIALS: REPORT OF AN ABTC WORKSHOP
  द्वारा: Grossman, Stuart, और अन्य
  प्रकाशित: (2019)
• Factors Influencing the CNS Distribution of a Novel MEK-1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases
  द्वारा: Vaidhyanathan, Shruthi, और अन्य
  प्रकाशित: (2014)
• Drug Delivery to Melanoma Brain Metastases: Can Current Challenges Lead to New Opportunities?
  द्वारा: Gampa, Gautham, और अन्य
  प्रकाशित: (2017)
• NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme
  द्वारा: Peereboom, David M., और अन्य
  प्रकाशित: (2013)
• Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier
  द्वारा: Laramy, Janice K., और अन्य
  प्रकाशित: (2018)